Rigontec GmbH, a German privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announced the first closing of its Series A financing round, raising €9.45 million.
Rigontec was launched in January 2014 as a spin-out of the Institute for Clinical Chemistry and Clinical Pharmacology at the University of Bonn, Germany. The Company’s co-founders, Prof. Gunther Hartmann and Prof. Veit Hornung, are internationally highly renowned scientific leaders in the area of innate immune recognition of viral nucleic acids and discovered 3pRNA as the ligand for RIG-I. The Company has access to the excellent infrastructure of the University Hospital Bonn, which includes state-of-the-art pre-clinical research facilities and a clinical trial unit. The company is developing synthetic ligands of a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I), which recognizes viral RNA. RNA motifs that activate RIG-I, promote the destruction of diseased cells and the induction of a lasting immune memory thereby treating and preventing recurrence of disease.
Rigontec’s lead compound ImOl100,